Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Cytokinetics (CYTK) Is Up 6.8% After MYQORZO FDA Approval Amid Insider Sales And Probe - What's Changed
Cytokinetics recently received FDA approval for MYQORZO (aficamten), a significant milestone for its cardiovascular franchise. While this de-risks the core oHCM thesis, the company faces ongoing shareholder investigations, persistent negative equity, and concerns about pipeline concentration and competition. The article highlights the contrast between regulatory success and internal challenges, emphasizing the need for robust commercialization and governance.